Cargando…
Incidence and survival of transthyretin amyloid cardiomyopathy from a French nationwide study of in- and out-patient databases
BACKGROUND: Precise data about ATTR-CM incidence rates at national level are scarce. Consequently, this study aimed to estimate the annual incidence and survival of transthyretin amyloid cardiomyopathy (ATTR-CM) in France between 2011 and 2019 using real world data. We used the French nationwide exh...
Autores principales: | Damy, Thibaud, Bourel, Guillaume, Slama, Michel, Algalarrondo, Vincent, Lairez, Olivier, Fournier, Pauline, Costa, Jérôme, Pelcot, Françoise, Farrugia, Agnès, Zaleski, Isabelle Durand, Lilliu, Hervé, Rault, Caroline, Bartoli, Mathilde, Fievez, Stéphane, Granghaud, Anna, Rudant, Jeremie, Coste, Agathe, Cosson, Charlotte Noirot, Squara, Pierre-Alexandre, Narbeburu, Marion, De Neuville, Bertrand, Charron, Philippe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10626733/ https://www.ncbi.nlm.nih.gov/pubmed/37926810 http://dx.doi.org/10.1186/s13023-023-02933-w |
Ejemplares similares
-
Expert opinion on monitoring symptomatic hereditary transthyretin-mediated amyloidosis and assessment of disease progression
por: Adams, David, et al.
Publicado: (2021) -
Impact of genotype and phenotype on cardiac biomarkers in patients with transthyretin amyloidosis – Report from the Transthyretin Amyloidosis Outcome Survey (THAOS)
por: Kristen, Arnt V., et al.
Publicado: (2017) -
Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the Transthyretin Amyloidosis Outcomes Survey (THAOS)
por: Damy, Thibaud, et al.
Publicado: (2019) -
Reply to the letter regarding the article ‘Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR‐ACT) and long‐term extension study’
por: Damy, Thibaud, et al.
Publicado: (2021) -
Deleterious effect of right ventricular pacing in patients with cardiac transthyretin amyloidosis: potential clinical benefit of cardiac resynchronization therapy
por: Aouate, David, et al.
Publicado: (2020)